Universal cancer tasks, evolutionary tradeoffs, and the functions of driver mutations

Recent advances have led to an appreciation of the vast molecular diversity of cancer. Detailed data has enabled powerful methods to sort tumors into groups with benefits for prognosis and treatment. We are still missing, however, a general theoretical framework to understand the diversity of tumor gene-expression and mutations. To address this, we present a framework based on multi-task evolution theory, using the fact that tumors evolve in the body, and that tumors are faced with multiple tasks that contribute to their fitness. In accordance with the theory, we find that tradeoff between tasks constrains tumor gene-expression to a continuum bounded by a polyhedron. The vertices of the polyhedron are gene-expression profiles each specializing in one task, allowing the tasks to be identified. We find five universal cancer tasks across tissue-types: cell-division, biomass & energy, lipogenesis, immune-interaction and invasion & tissue remodeling. Tumors whose gene-expression lies close to a vertex are task specialists. We find evidence that such specialists are more sensitive to drugs that interfere with this task. We find that driver mutations, but not passenger mutations, tune gene-expression towards specialization in specific tasks. This approach can integrate additional types of molecular data into a theoretically-based framework for understanding tumor diversity.

[1]  Ville Mustonen,et al.  Correction to: Landscape of somatic mutations in 560 breast cancer whole-genome sequences (Nature, (2016), 534, 7605, (47-54), 10.1038/nature17676) , 2019 .

[2]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[3]  N. Rosenfeld,et al.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes , 2016, Nature Communications.

[4]  A. Services,et al.  Integrated genomic and molecular characterization of cervical cancer. , 2017 .

[5]  Gerhard Christofori,et al.  Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? , 2016, Current opinion in cell biology.

[6]  Adam A. Margolin,et al.  Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity , 2012, Nature.

[7]  P. Ward,et al.  Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.

[8]  Robert A. Gatenby,et al.  Life history trade-offs in cancer evolution , 2013, Nature Reviews Cancer.

[9]  P. Sorger,et al.  Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs , 2016, Nature Methods.

[10]  C. Tognon,et al.  Reduced proliferation and enhanced migration: Two sides of the same coin? Molecular mechanisms of metastatic progression by YB-1 , 2009, Cell cycle.

[11]  Susan M. Butler,et al.  Going against the grain: chemotaxis and infection in Vibrio cholerae , 2005, Nature Reviews Microbiology.

[12]  Richard A. Moore,et al.  Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy , 2017, Nature.

[13]  M. Blasco Telomeres and human disease: ageing, cancer and beyond , 2005, Nature Reviews Genetics.

[14]  Johan Hartman,et al.  Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing , 2018, Cell.

[15]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[16]  Michael P. Schroeder,et al.  IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.

[17]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[18]  Allan Jacobson,et al.  NMD: a multifaceted response to premature translational termination , 2012, Nature Reviews Molecular Cell Biology.

[19]  Benjamin D. Simons,et al.  Defining the mode of tumour growth by clonal analysis , 2012, Nature.

[20]  Sebastian Munck,et al.  De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation. , 2010, Cancer research.

[21]  R. Deshaies,et al.  Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy , 2014, BMC Biology.

[22]  O Shoval,et al.  Evolutionary Trade-Offs, Pareto Optimality, and the Geometry of Phenotype Space , 2012, Science.

[23]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[24]  Dolph Schluter,et al.  ADAPTIVE RADIATION ALONG GENETIC LINES OF LEAST RESISTANCE , 1996, Evolution; international journal of organic evolution.

[25]  D. Sabatini,et al.  mTOR Signaling in Growth Control and Disease , 2012, Cell.

[26]  Krishnendu Chatterjee,et al.  Reconstructing metastatic seeding patterns of human cancers , 2017, Nature Communications.

[27]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[28]  Mark M. Davis,et al.  Cell type–specific gene expression differences in complex tissues , 2010, Nature Methods.

[29]  S. Beloribi-Djefaflia,et al.  Lipid metabolic reprogramming in cancer cells , 2016, Oncogenesis.

[30]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[31]  M. Simon,et al.  Hypoxia, lipids, and cancer: surviving the harsh tumor microenvironment. , 2014, Trends in cell biology.

[32]  T. Hubbard,et al.  A census of human cancer genes , 2004, Nature Reviews Cancer.

[33]  Y. Benjamini,et al.  Controlling the false discovery rate in behavior genetics research , 2001, Behavioural Brain Research.

[34]  C. Semenkovich,et al.  Peroxisomes: a nexus for lipid metabolism and cellular signaling. , 2014, Cell metabolism.

[35]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[37]  Krister Wennerberg,et al.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. , 2013, Cancer discovery.

[38]  Robert J Gillies,et al.  Eco-evolutionary causes and consequences of temporal changes in intratumoural blood flow , 2018, Nature Reviews Cancer.

[39]  Uri Alon,et al.  Inferring biological tasks using Pareto analysis of high-dimensional data , 2015, Nature Methods.

[40]  S. Ferdinandusse,et al.  Metabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic Reticulum , 2016, Front. Cell Dev. Biol..

[41]  M. Erlacher,et al.  How cell death shapes cancer , 2015, Cell Death and Disease.

[42]  K. Kinzler,et al.  Cancer Genome Landscapes , 2013, Science.

[43]  The Cancer Genome Atlas Research Network COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.

[44]  Steven J. M. Jones,et al.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.

[45]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[46]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[47]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[48]  Charles H. Yoon,et al.  Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq , 2016, Science.

[49]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[51]  Uri Alon,et al.  Evolutionary trade-offs and the structure of polymorphisms , 2018, Philosophical Transactions of the Royal Society B: Biological Sciences.

[52]  Michelle Monje,et al.  Neuronal Activity in Ontogeny and Oncology. , 2017, Trends in cancer.

[53]  Steven J. M. Jones,et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.

[54]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[55]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[56]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[57]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[58]  M. Stratton,et al.  A census of amplified and overexpressed human cancer genes , 2010, Nature Reviews Cancer.

[59]  Yuval Hart,et al.  Geometry of the Gene Expression Space of Individual Cells , 2015, PLoS Comput. Biol..

[60]  Emanuel J. V. Gonçalves,et al.  A Landscape of Pharmacogenomic Interactions in Cancer , 2016, Cell.

[61]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[62]  Ali Bashashati,et al.  Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes , 2017, Nature Genetics.

[63]  T. Hwa,et al.  Interdependence of Cell Growth and Gene Expression: Origins and Consequences , 2010, Science.

[64]  Andreas Wagner,et al.  Energy constraints on the evolution of gene expression. , 2005, Molecular biology and evolution.

[65]  S. Leibler,et al.  Bacterial Persistence as a Phenotypic Switch , 2004, Science.

[66]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[67]  Y. Liu,et al.  Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[68]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[69]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[70]  K. Schaller,et al.  'Go or grow': the key to the emergence of invasion in tumour progression? , 2012, Mathematical medicine and biology : a journal of the IMA.

[71]  Steven J. M. Jones,et al.  Integrated genomic and molecular characterization of cervical cancer , 2017, Nature.

[72]  Charles H. Graham,et al.  Hypoxia-driven selection of the metastatic phenotype , 2007, Cancer and Metastasis Reviews.

[73]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[74]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[75]  Adam B. Olshen,et al.  Integrative clustering of multiple genomic data types using a joint latent variable model with application to breast and lung cancer subtype analysis , 2009, Bioinform..

[76]  Carlos Caldas,et al.  A new genome‐driven integrated classification of breast cancer and its implications , 2013, The EMBO journal.

[77]  M. Lynch,et al.  The bioenergetic costs of a gene , 2015, Proceedings of the National Academy of Sciences.

[78]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[79]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[80]  Joshua M. Stuart,et al.  Subtype and pathway specific responses to anticancer compounds in breast cancer , 2011, Proceedings of the National Academy of Sciences.

[81]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[82]  D. Berger,et al.  Perineural invasion in cancer , 2009, Cancer.

[83]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[84]  J. Menéndez,et al.  Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis , 2007, Nature Reviews Cancer.

[85]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[86]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.